Principles of Drug Resistance and Cancer Precision Medicine

NCI Center for Cancer Research Eminent Lecture Series Dr. Levi Garraway is an Associate Professor of Medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, and a Senior Associate Member of the Broad Institute. He is the inaugural Director of the Joint Center for Cancer Precision Medicine at the Dana-Farber, Brigham and Women’s Hospital, and the Broad Institute, and co-Director of the Cancer Genetics Program at the Dana-Farber/Harvard Cancer Center. Dr. Garraway received his A.B. in Biochemical Sciences from Harvard College in 1990, and his M.D. and Ph.D. degrees from Harvard Medical School in 1999. Thereafter, he completed his internship and residency in Internal Medicine at the Massachusetts General Hospital, where he also served as Medical Chief Resident in 2003. He received fellowship training in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Garraway has made seminal research contributions in cancer genomics, drug resistance, and precision (or “personalized”) cancer medicine. He published the first whole genome sequencing studies of prostate cancer, and has led major cancer genomics initiatives in both melanoma and prostate cancer. This work has identified multiple new cancer genes and several fundamental mechanisms by which cancer may arise. He was also the first to describe ways in which an important subtype of melanoma becomes resistant to several new targeted therapies. His several major c...
Source: Videocast - All Events - Category: Journals (General) Tags: Upcoming Events Source Type: video